Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

189
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
189
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

130
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
130
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

702
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
702
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

644
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
644
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

770
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
770
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.1K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Towards safer medication use in older adults: Investigating barriers and facilitators of deprescribing.

British journal of clinical pharmacology·2025
Same author

Use of artificial intelligence (AI) in medical postgraduate training.

Journal of evaluation in clinical practice·2024
Same author

Inception of the Indian Digital Health Mission: <i>Connecting…the…Dots</i>.

Health care science·2024
Same author

Assessing the Efficacy of the ARMOR Tool-Based Deprescribing Intervention for Fall Risk Reduction in Older Patients Taking Fall Risk-Increasing Drugs (DeFRID Trial): Protocol for a Randomized Controlled Trial.

JMIR research protocols·2024
Same author

Efficacy and safety of Molnupiravir in COVID-19 patients: a systematic review.

Irish journal of medical science·2022
Same author

Precision medicine in diabetes-Finally some light at the end of the tunnel?

British journal of clinical pharmacology·2020

Related Experiment Video

Updated: Dec 12, 2025

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.9K

Dapagliflozin for heart failure: is it a class effect?

Gerard Marshall Raj1, Mukta Wyawahare2

  • 1Department of Pharmacology, Assistant Professor, Sri Venkateshwaraa Medical College Hospital & Research Centre (SVMCH & RC), Puducherry 605102, India.

Future Cardiology
|August 7, 2020
PubMed
Summary

Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, shows benefits in heart failure independent of glucose lowering. This offers new hope for managing cardiovascular events in patients with reduced ejection fraction.

Keywords:
SGLT2 inhibitorscanagliflozindapagliflozinempagliflozinheart failure

More Related Videos

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.2K
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

448

Related Experiment Videos

Last Updated: Dec 12, 2025

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.9K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.2K
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

448

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Sodium-glucose cotransporter 2 (SGLT2) inhibitors are primarily used for Type 2 diabetes mellitus management.
  • Recent approvals and label changes highlight the expanding role of SGLT2 inhibitors in cardiovascular care.
  • Dapagliflozin is now approved for managing worsening cardiovascular events in adults with heart failure with reduced ejection fraction.

Purpose of the Study:

  • To review the current understanding of SGLT2 inhibitors in heart failure management.
  • To highlight the cardiovascular benefits of dapagliflozin beyond its glucose-lowering effects.
  • To discuss the potential and current limitations in the therapeutic application of other SGLT2 inhibitors in heart failure.

Main Methods:

  • Literature review of clinical trials and regulatory approvals concerning SGLT2 inhibitors and heart failure.
  • Analysis of the mechanisms underlying the cardiovascular benefits of SGLT2 inhibitors.
  • Comparative overview of different SGLT2 inhibitors (dapagliflozin, canagliflozin, empagliflozin, ertugliflozin) in heart failure.

Main Results:

  • Dapagliflozin has demonstrated efficacy in reducing cardiovascular events, including deaths and hospitalizations, in patients with heart failure with reduced ejection fraction.
  • Canagliflozin's label was updated to include risk reduction for heart failure hospitalization in specific patient populations.
  • The cardiovascular benefits of dapagliflozin appear to be independent of its glucose-lowering and SGLT2-inhibiting effects, suggesting novel mechanisms of action.

Conclusions:

  • SGLT2 inhibitors, particularly dapagliflozin, represent a significant advancement in heart failure management.
  • Further research is needed to fully delineate the role of empagliflozin and ertugliflozin in heart failure.
  • The pleiotropic effects of SGLT2 inhibitors offer a promising therapeutic avenue for cardiovascular disease.